We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
Read MoreHide Full Article
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Akero Therapeutics, Inc. (AKRO - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Akero Therapeutics, Inc. is one of 961 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Akero Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AKRO's full-year earnings has moved 4.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, AKRO has returned 70.7% so far this year. In comparison, Medical companies have returned an average of -0.4%. As we can see, Akero Therapeutics, Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Humana (HUM - Free Report) . The stock is up 2.6% year-to-date.
For Humana, the consensus EPS estimate for the current year has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Akero Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 472 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, this group has gained an average of 4.9% so far this year, meaning that AKRO is performing better in terms of year-to-date returns.
Humana, however, belongs to the Medical - HMOs industry. Currently, this 8-stock industry is ranked #215. The industry has moved -26% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Akero Therapeutics, Inc. and Humana as they attempt to continue their solid performance.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Is Akero Therapeutics (AKRO) Stock Outpacing Its Medical Peers This Year?
For those looking to find strong Medical stocks, it is prudent to search for companies in the group that are outperforming their peers. Is Akero Therapeutics, Inc. (AKRO - Free Report) one of those stocks right now? A quick glance at the company's year-to-date performance in comparison to the rest of the Medical sector should help us answer this question.
Akero Therapeutics, Inc. is one of 961 individual stocks in the Medical sector. Collectively, these companies sit at #4 in the Zacks Sector Rank. The Zacks Sector Rank considers 16 different groups, measuring the average Zacks Rank of the individual stocks within the sector to gauge the strength of each group.
The Zacks Rank is a successful stock-picking model that emphasizes earnings estimates and estimate revisions. The system highlights a number of different stocks that could be poised to outperform the broader market over the next one to three months. Akero Therapeutics, Inc. is currently sporting a Zacks Rank of #2 (Buy).
The Zacks Consensus Estimate for AKRO's full-year earnings has moved 4.9% higher within the past quarter. This means that analyst sentiment is stronger and the stock's earnings outlook is improving.
Based on the most recent data, AKRO has returned 70.7% so far this year. In comparison, Medical companies have returned an average of -0.4%. As we can see, Akero Therapeutics, Inc. is performing better than its sector in the calendar year.
One other Medical stock that has outperformed the sector so far this year is Humana (HUM - Free Report) . The stock is up 2.6% year-to-date.
For Humana, the consensus EPS estimate for the current year has increased 3.8% over the past three months. The stock currently has a Zacks Rank #2 (Buy).
Looking more specifically, Akero Therapeutics, Inc. belongs to the Medical - Biomedical and Genetics industry, which includes 472 individual stocks and currently sits at #80 in the Zacks Industry Rank. On average, this group has gained an average of 4.9% so far this year, meaning that AKRO is performing better in terms of year-to-date returns.
Humana, however, belongs to the Medical - HMOs industry. Currently, this 8-stock industry is ranked #215. The industry has moved -26% so far this year.
Investors interested in the Medical sector may want to keep a close eye on Akero Therapeutics, Inc. and Humana as they attempt to continue their solid performance.